top of page



Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder.

Poleg S, Kourieh E, Ruban A, Shapira G, Shomron N, Barak B, Offen D.Transl Psychiatry. 2021 Oct 13;11(1):524. doi: 10.1038/s41398-021-01612-3.

Intranasal delivery of mesenchymal stem cells-derived extracellular vesicles for the treatment of neurological diseases.

Herman S, Fishel I, Offen D.Stem Cells. 2021 Dec;39(12):1589-1600. doi: 10.1002/stem.3456. Epub 2021 Oct 1.

Single-Base Resolution: Increasing the Specificity of the CRISPR-Cas System in Gene Editing.

Rabinowitz R, Offen D. Molecular Therapy. 2021 Mar 3;29(3):937-948. 

Induced neural differentiation of human mesenchymal stem cells affects lipid metabolism pathways. Pnina Green, Inna Kan, Ronit Mesilati-Stahy, Nurit Argov-Argaman, Daniel Offen. January 18, 2021.bioRxiv preprint doi:


Increased RNA editing in maternal immune activation model of neurodevelopmental disease. 

Tsivion-Visbord, H., Kopel, E., Feiglin, A., Sofer, T., Barzilay, R., Ben-Zur, T., Yaron, O., Offen, D. and Levanon, E.Y., 2020. Nature Communications, 11(1), pp.1-13.

ND-13, a DJ-1-Derived Peptide, Attenuates the Renal Expression of Fibrotic and Inflammatory Markers Associated with Unilateral Ureter Obstruction.

De Miguel, Carmen, Abigayle C. Kraus, Mitchell A. Saludes, Prasad Konkalmatt, Almudena Ruiz Domínguez, Laureano D. Asico, Patricia S. Latham, Daniel Offen, Pedro A. Jose, and Santiago Cuevas.  International Journal of Molecular Sciences 21, no. 19 (2020): 7048.;

Promising Opportunities for Treating Neurodegenerative Diseases with Mesenchymal Stem Cell-Derived Exosomes.

Guy R, Offen D.Biomolecules. 2020 Sep 15;10(9):E1320. doi: 10.3390/biom10091320.

Mesenchymal stem cells derived extracellular vesicles improve behavioral and biochemical deficits in a phencyclidine model of schizophrenia. 

Tsivion-Visbord, H., Perets, N., Sofer, T. et al. Transl Psychiatry 10, 305 (2020).

Exosomes derived from mesenchymal stem cells improved core symptoms of genetically modified mouse model of autism Shank3B.

Perets N, Oron O, Herman S, Elliott E, Offen D.Mol Autism. 2020 Aug 17;11(1):65. doi: 10.1186/s13229-020-00366-x.

CrisPam: SNP-Derived PAM Analysis Tool for Allele-Specific Targeting of Genetic Variants Using CRISPR-Cas Systems.

Rabinowitz R, Almog S, Danell R, Offen D. Front. Genet., 18 August 2020. doi: 10.3389/fgene.2020.00851

Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson's disease.

Kahana M, Weizman A, Gabay M, Loboda Y, Segal-Gavish H, Gavish A, Barhum Y, Offen D, Finberg J, Allon N, Gavish M.

Mol Psychiatry. 2020 May 5. doi: 10.1038/s41380-020-0742-4

A novel specific PERK activator reduces toxicity and extends survival in Huntington's disease models.

Ganz J, Shacham T, Kramer M, Shenkman M, Eiger H, Weinberg N, Iancovici O, Roy S, Simhaev L, Da'adoosh B, Engel H, Perets N, Barhum Y, Portnoy M, Offen D, Lederkremer GZ.

Sci Rep. 2020 Apr 23;10(1):6875. doi: 10.1038/s41598-020-63899-4.

Prediction of synonymous corrections by the BE-FF computational tool expands the targeting scope of base editing.

Rabinowitz R, Abadi S, Almog S, Offen D.

Nucleic Acids Res. 2020 Apr 7. pii: gkaa215. doi: 10.1093/nar/gkaa215. 

Caspase-6 Knockout in the 5xFAD Model of Alzheimer's Disease Reveals Favorable Outcome on Memory and Neurological Hallmarks.

Angel A, Volkman R, Royal TG, Offen D.

Int J Mol Sci. 2020 Feb 9;21(3). pii: E1144. doi: 10.3390/ijms21031144.

Genes to treat excitotoxicity ameliorate the symptoms of the disease in mice models of multiple system atrophy.

Glat MJ, Stefanova N, Wenning GK, Offen D.

J Neural Transm (Vienna). 2020 Feb;127(2):205-212. doi: 10.1007/s00702-020-02158-2. Epub 2020 Feb 17.

bottom of page